Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Enlicitide

Drug and asset intelligence for Enlicitide with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
2
Catalysts
2
Stage
Development stage unavailable

Sponsor company

Merck →

Mechanism of action

Hormonal Therapy

Recent signals(2)

RegulatoryJuly 18, 2026

FDA Grants Approval for Enlicitide by Merck Sharp and Dohme

The FDA has granted approval for Enlicitide, an original application by Merck Sharp and Dohme.

ClinicalJune 24, 2026

Merck's Enlicitide Study Aims to Enhance LDL-C Reduction with Rosuvastatin

Merck is conducting a clinical trial to evaluate the efficacy of enlicitide in combination with rosuvastatin for lowering LDL-C levels.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

(2)

Topline Data

Merck — Enlicitide

July 18, 2026 · N/A

Topline Data

Merck — Enlicitide

June 24, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Cardiology →
Cardiology · LDL-C Lowering →
Endocrinology →
Endocrinology · Hormonal Therapy →
Hormonal Therapy →
LDL-C Lowering →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.